Half-year report · Q2
4272.TEDINET S100UPTW
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥109.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥201.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥97.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥11.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥4.8bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥11.7bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥12.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥8.6bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥6.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥356.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥363.2bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥349.2bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥92.4bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥92.6bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥264.2bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥270.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥267.5bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥50.7bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥56.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥52.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥14.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥16.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥19.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥9.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥36.21 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.8 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.74 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥36.2 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.79 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.72 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 73.8% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥87m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥87m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.4bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥32.7bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥32.6bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥87m |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥46.0bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥46.0bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥109.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥109.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥87m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥78m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥78m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥3.9bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥28.0bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥27.9bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥77m |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥39.5bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥39.5bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥98.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥97.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥78m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 576
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in inventories ope cf | CurrentYTDDuration | -5669000000 | JPY |
| Decrease increase in prepaid expenses ope cf | Prior1YTDDuration | -762000000 | JPY |
| Decrease increase in prepaid expenses ope cf | CurrentYTDDuration | -388000000 | JPY |
| Decrease increase in accounts receivable other ope cf | Prior1YTDDuration | 230000000 | JPY |
| Decrease increase in accounts receivable other ope cf | CurrentYTDDuration | 586000000 | JPY |
| Decrease increase in advance payments ope cf | Prior1YTDDuration | -249000000 | JPY |
| Decrease increase in advance payments ope cf | CurrentYTDDuration | -156000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 4221000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 3658000000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1YTDDuration | 134000000 | JPY |
| Increase decrease in accounts payable other ope cf | CurrentYTDDuration | -1304000000 | JPY |
| Increase decrease in accrued expenses ope cf | Prior1YTDDuration | 103000000 | JPY |
| Increase decrease in accrued expenses ope cf | CurrentYTDDuration | 789000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | 11000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | -12000000 | JPY |
| Increase decrease in net defined benefit asset ope cf | Prior1YTDDuration | -153000000 | JPY |
| Increase decrease in net defined benefit asset ope cf | CurrentYTDDuration | -306000000 | JPY |
| Other net ope cf | Prior1YTDDuration | 262000000 | JPY |
| Other net ope cf | CurrentYTDDuration | 574000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 12635000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 15689000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 1165000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 1214000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -44000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -73000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -3348000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -2493000000 | JPY |
| Income taxes refund ope cf | Prior1YTDDuration | 114000000 | JPY |
| Income taxes refund ope cf | CurrentYTDDuration | 437000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 10523000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 14774000000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -317000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -22000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 21000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 22000000 | JPY |
| Payments of short term loans receivable inv cf | Prior1YTDDuration | -139000000 | JPY |
| Payments of short term loans receivable inv cf | CurrentYTDDuration | -154000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -6568000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -14253000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | 190000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | 0 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -139000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -726000000 | JPY |
| Purchase of short term investment securities inv cf | Prior1YTDDuration | － | JPY |
| Purchase of short term investment securities inv cf | CurrentYTDDuration | -108000000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -6553000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -863000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | 1718000000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | 18000000 | JPY |
| Collection of short term loans receivable inv cf | Prior1YTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |